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Abstract
Introduction Cardiopulmonary bypass (CPB) induces
hemodilutional anemia, which frequently requires the transfusion
of blood products. The objective of this study was to evaluate
oxygen delivery and consumption and clinical outcome in low
risk patients who were allocated to an hematocrit (Hct) of 20%
versus 25% during normothermic CPB for elective coronary
artery bypass graft (CABG) surgery.
Methods This study was a prospective, randomized and
controlled trial. Patients were subjected to normothermic CPB
(35 to 36°C) and were observed until discharge from the
intensive care unit (ICU). Outcome measures were calculated
whole body oxygen delivery, oxygen consumption and clinical
outcome. A nonparametric multivariate analysis of variance for
repeated measurements and small sample sizes was performed.
Results In a total of 54 patients (25% Hct, n = 28; 20% Hct, n
= 26), calculated oxygen delivery (p  = 0.11), oxygen
consumption (p = 0.06) and blood lactate (p = 0.60) were not
significantly different between groups. Clinical outcomes were
not different between groups.
Conclusion These data indicate that an Hct of 20% during
normothermic CPB maintained calculated whole body oxygen
delivery above a critical level after elective CABG surgery in low
risk patients. The question of whether a transfusion trigger in
excess of 20% Hct during normothermic CPB is still supported
requires a larger prospective and randomized trial.
Introduction
Hemodilution occurs during cardiac surgery when cardiopul-
monary bypass (CPB) is instituted. Hemodilution reduces
blood viscosity and vascular resistance, and may increase
large vessel blood flow to maintain whole body oxygen delivery
[1]. It does appear that the microcirculation can regulate red
cell flow and concentration over a wide range of hematocrit
(Hct) levels [2]. Of interest, a 43% increase in cerebral blood
flow has been described for a 31% reduction in hemoglobin
concentration during CPB [3].
Debate exists on the minimum safe level Hct necessary to
maintain oxygen delivery (DO2) during CPB. Hct level is used
as a measure for triggering transfusion, but transfusion carries
a wide range of complications and appears to worsen out-
come after coronary artery bypass graft (CABG) surgery [4].
Moreover, it was shown that aged red blood cells from the
blood bank delivered less oxygen to tissue than fresh blood [5]
and transfusion of allogeneic red blood cells was ineffective in
improving skeletal muscle oxygen tension after CABG surgery
compared to ventilation with 100% oxygen [6]. Results from
CABG = coronary artery bypass graft; CPB = cardiopulmonary bypass; DO2 = oxygen delivery; Hct = hematocrit; ICU = intensive care unit; MAP = 
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the literature do demonstrate a relationship between low Hct
and adverse outcomes. Fang and colleagues [7] found a dou-
bling (2.7-fold) of mortality when the lowest nadir Hct reached
14% during CPB. Later, Defoe and co-workers [8] reported
that an Hct <19% during CPB was associated with a two-fold
increase in hospital mortality and a trend towards increased
risk of death for an HCT <23%. Neither Fang and colleagues
nor Defoe and colleagues investigated transfusion as a covari-
ate or confounder. It could well be that these data were driven
by transfusion risks and not critical Hct and oxygen delivery. In
a recent study, Habib and colleagues [9] described a sigmoi-
dal association between the extent of hemodilutional anemia
and acute renal failure after cardiac surgery. The relationship
between nadir hematocrit and acute renal failure was wors-
ened by intra-operative transfusions in this study. The authors
concluded that hemodilutional anemia did not necessarily
cause but increased the likelihood of acute renal failure. Fur-
thermore, transfusion of packed red blood cells may not be the
appropriate treatment for renal injury. This study supports the
hypothesis that transfusion may be a risk factor for acute renal
failure after CPB.
Most data on the relationship between hemodilutional anemia
and outcome have been measured during hypothermic (28 to
32°C), moderate hypothermic (32 to 34°C) or normothermic
CPB. Temperature regulation favoring hypothermia during
CPB was found to reduce cerebral oxygen consumption [10],
preserve myocardial function [11] and to reduce whole body
oxygen metabolism [12]. However, normothermia for CPB has
emerged as an alternative technique for temperature regula-
tion during CPB [13] that has been associated with a compa-
rable clinical outcome [14,15]. Hemodilution to an Hct of 0.10
(± 0.02) has been shown to increase cerebral blood flow com-
pared to baseline to a greater extent at 38°C than at 28°C, and
at 28°C than at 18°C [16]. Cerebral metabolic rate (CMRO2)
was kept stable at Hct levels of 0.14, 0.11 and 0.10 in the
respective temperature groups. The authors of this animal
study concluded that the compensatory increase in cerebral
blood flow at an Hct of 0.14 met the increased rate of cerebral
oxygen demand even at a body temperature of 38°C. Although
results from controlled clinical studies reported similar or ben-
eficial outcome after normothermic CPB [17,18], cardiac sur-
gical practice still performs CPB over a broad range of
temperatures.
Results from controlled trials investigating the effect of
hemodilution on oxygen delivery and clinical outcome in
patients undergoing normothermic CPB have not yet been
published. Therefore, the objective of this prospective, rand-
omized and controlled study was to investigate oxygen deliv-
ery and consumption and the clinical outcome of patients who
were randomly allocated to one of two Hcts (20% or 25%)
during normothermic CPB.
Materials and methods
Group assignment
After institutional approval by the local ethics committee and
preoperative written informed consent, 57 patients were con-
sidered eligible for this randomized, controlled clinical trial
from February 2004 until November 2004. Patients were allo-
cated to the trial groups according to a computer-generated
random list. One patient had to be excluded from analysis as
the donated autologous blood showed multiple clots and
could not be retransfused. Informed consent was withdrawn
by one patient and one patient had to be excluded due to the
preoperative decision for a combined surgical procedure. In
total, 54 patients (28 in the 25% Hct group and 26 in the 20%
Hct group) remained for statistical analysis according to the
Full Analysis Set (Intention To Treat).
Inclusion criteria were age >18 and <75 years, elective coro-
nary artery bypass graft surgery, weight >70 kg and preoper-
ative Hct >36% (hemoglobin >12 g/dl).
Exclusion criteria were withdrawal of consent, Jehova's Wit-
nesses, stroke in patient's history or with persistent neurolog-
ical residue, unilateral occlusion of carotid artery >70% or
bilateral occlusion of carotid artery >50%, combined cardiac
procedure, left ventricular ejection fraction <40%, unstable
angina, a left main stem stenosis >70%, ventricular arrhythmia
>LOWN IVa, symptomatic chronic pulmonary disease requir-
ing long-term medication or FEV1 <70% or FEV1/VC max
<70% or partial pressure of oxygen in arterial blood (paO2)
<60 mmHg, known acute or chronic hepatitis or hepatic dis-
ease with impaired synthesis of coagulation factors or bilirubin
>2.0 mg/dl, known inflammatory bowel disease, known renal
insufficiency or anuric renal failure or creatinine >1.5 mg/dl,
ingestion of aspirin or clopidogrel until 3 days prior to surgery,
and treatment with glycoprotein-receptor antagonists within 2
days before surgery. Furthermore, patients were excluded
from the study if the Hct could not maintained within the tar-
geted range during CPB, if an emergency situation (for exam-
ple, cardiopulmonary resuscitation, acute right or left
ventricular failure) occurred before initiation of CPB and if the
autologous blood could not be retransfused.
Anesthetic and CPB technique, isovolemic hemodilution 
and management in the intensive care unit
The standard anesthetic practice was an opioid-based anes-
thetic supplemented with midazolam and isoflurane as
required. In all patients, a femoral artery was cannulated with a
4-Fr.-cannula (Pulsiocath, Pulsion, Munich, Germany) prior to
induction of anesthesia. A central venous catheter and a pul-
monary artery catheter (Thermodilution Catheter, Arrow, Read-
ing, PA, USA) were inserted via the right internal jugular vein.
The standardized CPB priming consisted of 600 ml of crystal-
loid fluid, 500 ml of 10% hydroxyethylstarch solution and a
total dose of 50,000 KIU aprotinin per kg bodyweight prior toAvailable online http://ccforum.com/content/10/2/R58
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and during CPB. Pump flow was adjusted to maintain a mean
arterial pressure (MAP) of 55 to 60 mmHg and an oxygen sat-
uration >75% during CPB. Norepinephrine was used during
CPB when MAP could not be maintained within the targeted
range by adjusting the pump flow. During bypass an arterial
partial pressure of oxygen of 150 to 250 mmHg was main-
tained. Body temperature was kept between 35.5 and 36°C
during CPB. CPB technique was normothermic using intermit-
tent antegrade warm blood cardioplegia as described by
Calafiore and colleagues [19]. Before institution of CPB, isov-
olemic hemodilution using a hydroxyethylstarch solution 130/
0.4 (Voluven®, Fresenius-Kabi, Bad Homburg, Germany) was
performed to reduce the Hct to a level of 5 ± 1% above the
target Hct level of 20 ± 1% or 25 ± 1%. For all measurements
of Hct and blood lactate, a blood gas analyzer (ABL-700
series, Radiometer, Copenhagen, Denmark) was used.
Measurements of Hct were done 2 and 5 minutes after initia-
tion of CPB and every 15 minutes when the target hematocrit
was stable. In cases where the initial Hct exceeded the tar-
geted Hct range, crystalloid fluid was substituted, and if the
hematocrit was below the target range, autologous blood was
transfused.
In the intensive care unit (ICU), patients were extubated as
soon as possible after an observation period of 6 hours if they
fulfilled the following criteria: paO2  >60 mmHg with an
inspired oxygen fraction (FiO2) of 40%, adequate neurological
reaction and sufficient muscle strength. Packed red blood
cells were substituted according to the following protocol: Hct
<23% or lactic acidosis or ST-segment elevation or secondary
organ failure attributed to hemodilutional anemia. In the ICU,
the patients were not infused with crystalloids according to a
standard protocol. Hydroxyethylstarch solution (6% HES 130/
0.4) was given when patients showed clinical symptoms of
hypovolemia.
Discharge from ICU to the intermediate care unit was feasible
when patients were in a stable clinical condition, that is, awake
without neurological deficit or agitation, = 5 µg/kg/minute
dopamine or no inotrope support, paO2 >60 mmHg with an
oxygen insufflation of 4 l per minute and a normal partial pres-
sure of carbon dioxide in arterial blood (paCO2) and no need
for continuous loop diuretics to maintain urinary output or renal
replacement therapy.
Outcome measures
Primary outcome measures of this trial were calculated whole
body oxygen delivery, oxygen consumption and mixed venous
blood lactate during CPB, at the end of surgery and in the ICU
(one, six and 18 hours after admission). Secondary outcome
measures were: drainage loss, transfusion utilization and Hct
in the ICU, incidence of secondary organ failure, hemodynamic
parameters and stay in ICU.
Oxygen delivery and oxygen consumption were calculated
using standard formulae (see Additional file 1). Hemodynamic
parameters such as MAP, central venous pressure, mean pul-
monary artery pressure and pulmonary artery occlusion pres-
sure were measured before hemodilution, at the end of surgery
after retransfusion of autologous blood, one and six hours after
admission to the ICU and before discharge from the ICU. Car-
diac index, systemic vascular resistance and pulmonary vascu-
lar resistance were calculated using standard formulas
Table 1
Basic patient characteristics
Characteristic Hematocrit 25% Hematocrit 20% p
Median IQR Median IQR
Age (years) 60 55–67 65 58–71 0.10
Gender (male/-female) 28/2 26/0 0.49
Height (m) 1.78 1.73–1.81 1.75 1.72–1.79 0.35
Weight (kg) 93 80–100 87 80–100 0.52
Body mass index (kg/m2) 27.9 26.0–32.2 28.8 26.7–29.9 0.72
Preoperative hematocrit (%) 41.8 40.2–43.0 42.1 39.4–45.4 0.88
Duration of anesthesia (minutes) 300 290–320 310 290–325 0.26
Duration of surgery (minutes) 190 160–220 205 175–250 0.09
CPB time (minutes) 72 55–83 73 63–81 0.50
Aortic cross clamp time (minutes) 45 33–56 45 38–49 0.93
APACHE II score 14 9–19 16 13–27 0.09
APACHE, Acute Physiology and Chronic Health Evaluation; CPB, cardiopulmonary bypass; IQR, interquartile range.Critical Care    Vol 10 No 2    von Heymann et al.
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whereas extravascular lung water and intrathoracic blood vol-
ume index were calculated at the same time points using the
PiCCO plus-monitor (Pulsion, Munich, Germany). During
CPB, pump-driven cardiac index, body temperature and blood
lactate were recorded 15 minutes after institution and at the
end of CPB whereas the cumulative amount of norepinephrine
and urine volume were taken at the end of CPB. The incidence
of acute cardiac failure, defined as need for epinephrine and/
or enoximone, the need for intraaortic balloon counterpulsation
for separation from CPB, and the dosage of dopamine for
weaning from CPB were recorded.
In the ICU, the following indicators for secondary organ failure
were assessed: neurological complications defined as transi-
tory ischemic attack, agitated arousal reaction or palsy of
extremities or hemiplegia. Myocardial infarction was deter-
mined by electrocardiogram (new Q-wave, ST-elevations >2
mm) and a ratio of creatine kinase and myocardial subtype of
creatine kinase >10%. Acute cardiac failure was defined as
the need for inotrope support (epinephrine, norepinephrine or
phosphodiesterase inhibitors), respiratory failure as the need
for reintubation due to respiratory failure, prolonged respira-
tory support (>24 hours) or the need for continuous positive
airway pressure breathing. Renal insufficiency was assumed
when patients required renal replacement therapy, continuous
intravenous loop diuretics or increase of creatinine >2.0 mg/
dl. Additionally, chest drainage loss, transfusion requirements
and Hct, cumulative urine volume, creatinine, ICU stay in hours
and mortality were recorded.
Statistical methods
Because of the limited sample sizes and/or non-symmetrically
distributed observations we applied only nonparametric statis-
tics. Results were expressed as median and interquartile range
in the case of continuous variables. Absolute and relative fre-
quencies were used for categorical and dichotomous varia-
bles. The effect of hemodilution regarding primary and
secondary outcomes was analyzed using χ2 or Fisher's exact
test for categorical and dichotomous variables, respectively. In
the case of continuous variables, we applied the Mann-Whit-
ney U test for inter-group analysis. A non-parametric multivari-
ate analysis of variance (nonparametric MANOVA) for
repeated measurements and small sample sizes in two and
three-factorial designs [20], respectively, was performed in
order to take the whole time courses into consideration simul-
taneously. Multiple tests for differences between the groups in
question have been regarded as exploratory ones and were
not adjusted for multiplicity. A two-tailed p < 0.05 was consid-
ered statistically significant. The statistical analysis was per-
formed using SPSS for Windows, 11.0 (SPSS, Inc., Chicago,
IL, USA).
Results
Basic patient characteristics (Table 1) did not differ between
the groups. The majority of patients were men (n = 52) with
two women who were randomized in the higher hematocrit
group.
Figure 1 gives the results for oxygen delivery and consumption
throughout the study period. Calculated oxygen delivery differ-
ences between groups almost reached statistical significance
Figure 1
Oxygen delivery (DO2) and oxygen consumption (VO2) during the study  period Oxygen delivery (DO2) and oxygen consumption (VO2) during the study 
period. *p < 0.05. ICU, intensive care unit.
Figure 2
Blood lactate during the study period Blood lactate during the study period. CPB, cardiopulmonary bypass; 
ICU, intensive care unit.Available online http://ccforum.com/content/10/2/R58
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at the end of surgery (767 versus 647 ml/m2/minute, p =
0.07). Oxygen consumption was significantly lower in the 20%
Hct group 6 hours after admission to the ICU (299 versus 246
ml/m2/minute, p = 0.05). In the non-parametric MANOVA the
difference in oxygen delivery did not remain significant (p =
0.11) between groups over the study period whereas oxygen
consumption tended to be lower (p = 0.06) in the 20% Hct
group. The blood lactate levels were not different between
groups throughout the study period (Figure 2). For blood lac-
tate, the non-parametric MANOVA did not find a significant dif-
ference between groups throughout the study period (p =
0.6).
The Hct was significantly lower in the 20% Hct group from the
end of surgery until the end of ICU stay (Figure 3). Notably, an
Hct of 30% was reached in the 20% Hct group at 6 hours
after admission to the ICU (30.0 versus 33.1%, p < 0.01). The
non-parametric MANOVA confirmed the significantly lower
Hct levels in the 20% Hct group (p < 0.01).
Table 2 shows intra-operative results (hemodynamic measure-
ments, dosage of norepinephrine, urine volume during CPB)
that were measured prior to, during and after CPB. All intra-
operative measures were not significantly different between
groups.
The clinical outcome in the ICU with regard to chest drainage
loss, transfusion use and secondary organ failure are given in
Table 3. Blood loss from chest drainage (p = 0.28), the inci-
dence of neurological complications (p = 0.99), cardiac (p =
0.99), respiratory (p = 0.99) and renal failure (p = 0.99) and
the combined endpoint of organ failure (p = 0.57) were not dif-
ferent between the groups. Five patients in the 20% Hct group
and one patient in the 25% Hct group (p = 0.10) were trans-
fused in the ICU. In particular, no acute myocardial infarction
was recorded. ICU stay in hours was not significantly different
between the groups.
One patient in the 20% Hct group died of septic multi-organ
failure due to pneumonia occurring on postoperative day 3,
accounting for the overall mortality of 1.9% (Table 3).
Discussion
Oxygen delivery, oxygen consumption and blood lactate
This study demonstrated that an Hct of 20% during normoth-
ermic CPB for elective CABG surgery did not 'critically'
reduce calculated whole body oxygen delivery. Over the study
period, calculated oxygen delivery was maintained above a
critical threshold of 330 ml/minute/m2 in anesthetized humans,
Table 2
Intraoperative outcome measures
Outcome measure Hematocrit 25% Hematocrit 20% p
Median IQR Median IQR
CI during CPB (l/m2/minute) 3.2 3.0–3.7 3.2 3.0–3.5 0.57
Temperature during CPB (°C) 35.6 35.0–36.0 36.8 35.4–36.0 0.12
Cumulative norepinephrine dosage during CPB (mg) 0.08 0.06–0.10 0.03 0.0–0.08 0.13
Dopamine dosage for weaning from CPB (µg/kg/minute) 1.0 0.0–3.0 1.5 0.0–3.0 0.92
Patients with catecholamines for weaning from CPB (n)1 6 1 6 0 . 7 9
Patients with intraaortic balloon pump for weaning from CPB (n)2 0 0 . 4 9
Patients with acute cardiac failure during weaning from CPB (n)3 2 1 . 0 0
Urine volume during CPB (ml) 159 97–354 165 102–440 0.57
CI, cardiac index; CPB, cardiopulmonary bypass; IQR, interquartile range.
Figure 3
Hematocrit during the study period Hematocrit during the study period. *p < 0.05. CPB, cardiopulmonary 
bypass; ICU, intensive care unit.Critical Care    Vol 10 No 2    von Heymann et al.
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as reported by Shibutani and colleagues [21]. An increase in
cardiac index in the 20% Hct group (Table 4) may have com-
pensated for the reduction in oxygen carrying capacity and
prevented DO2 from being significantly reduced. It may also be
that the microcirculation compensated for the differences in
Hct levels used in our study [2]. Mathru and colleagues [22]
reported results from 8 anesthetized patients who were
exposed to an Hct of 15% after elective CABG surgery and a
body temperature of 37°C, which led to a significant, but not
'critical', reduction in DO2. Patients in the 20% Hct group
used significantly less oxygen in the ICU (at six hours after
admission; Figure 1). In both groups, oxygen consumption
continuously increased from the lowest values at the end of
surgery to the highest values before discharge from the ICU
while oxygen delivery was maintained well above critical levels.
Forces upon oxygen consumption during the ICU period and
after extubation, which include, for example, lower level of
sedation, increased muscular activity, fever or pain, may have
caused the increase in oxygen consumption. Prior work in
awake humans has shown that oxygen consumption is stable
until an Hct of 15% [23], indicating that hemodilution alone
may not change oxygen consumption. Since the oxygen
extraction rate also increased over the study period in both
groups (Figure 1), a higher whole body oxygen demand has to
be assumed. A similar increase in oxygen consumption and
oxygen extraction rate was reported to occur in general sur-
gery [24] and cardiac surgical patients [25] and seems to rep-
resent a hypermetabolic response to the surgical trauma
rather than to CPB [25].
Both groups had normal blood lactate levels throughout the
study, indicating that a gross mismatch of whole body oxygen
delivery and consumption during CPB did not occur. This fur-
ther supports our conclusion that hemodilution to 20% Hct
maintained DO2 above a critical level and may be considered
safe in regard to adequate whole body oxygen supply in nor-
mothermic CPB for elective CABG surgery in low risk
patients.
Clinical outcome
The clinical outcome in regard to drainage loss, transfusion
requirements and secondary organ failure were not different
between the study groups. In particular, no myocardial infarc-
tion was detected in our group of patients, which may support
the hypothesis that myocardial oxygen delivery during and
after CPB was maintained in the 20% Hct group. Our results
are in accordance with previous results that an Hct of <34%
on admission to the ICU (25.8% versus 23.5% in our study
groups, respectively was not associated with a significantly
higher rate of myocardial ischemia [26].
Table 3
Outcome measures in the intensive care unit
Outcome measure Hematocrit 25% Hematocrit 20% p
Median IQR Median IQR
Number of transfused patients 1 5 0.10
Drainage loss (ml) 382 265–530 400 290–620 0.28
Patients with postoperative stroke (n)0 0 0 . 9 9
Patients with agitated arousal reaction (n)3 3 0 . 9 9
Patients with myocardial infarction (n)0 0 0 . 9 9
CK/CK-MB ratio (%) 6.25 4.8–7.2 5.9 4.4–7.0 0.99
Patients with catecholamines on admission to ICU (n) 10 7 0.57
Patients with catecholamines 6 h after admission to ICU (n) 5 2 0.42
Patients with dopamine 18 h after admission to ICU (n)2 1 0 . 5 3
Patients with respiratory failure (n)3 3 0 . 9 9
Duration of ventilator support (hours) 10 8–12,5 10 10–12 0.36
Patients with renal failure (n)1 1 0 . 9 9
Creatinine 18 h after admission to ICU (mg/dl) 0.92 0.82–1.19 1.06 0.90–1.14 0.30
Urine volume in ICU (ml) 2.810 2.390–3.469 2.815 2.100–3.600 0.82
Combined endpoint of organ failure (n) 8 10 0.57
Duration of ICU stay (hours) 22 21–24 23 21–28 0.24
Mortality (n)0 1 0 . 4 8
CK, creatine kinase; CK-MB, myocardial creatine kinase; ICU, intensive care unit; IQR, interquartile range.Available online http://ccforum.com/content/10/2/R58
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Table 4
Hemodynamic measurements and parameters of oxygen metabolism
Hematocrit 25% Hematocrit 20% p
Median IQR Median IQR
Before hemodilution
MAP (mmHg) 71 67–80 67 62–76 0.28
CVP (mmHg) 12 10–16 12 8–14 0.13
MPAP (mmHg) 21 17–26 19 17–22 0.17
PAOP (mmHg) 13 9–14 12 10–14 0.68
CI (l/minute/m2) 2.09 1.87–2.41 2.13 1.91–2.43 0.97
SVR (dyn/s/cm-5) 1083 863–1,269 1117 854–1,379 0.49
PVR (dyn/s/cm-5) 140 107–214 130 95–154 0.31
EVLWI (ml/kg/m2) 7.0 6.0–9.0 7.0 7.0–8.0 0.62
ITBVI (ml/kg/m2) 798 704–925 754 672–793 0.11
At the end of surgery
MAP (mmHg) 69 64–87 66 59–79 0.15
CVP (mmHg) 8 6–12 10 9–14 0.22
MPAP (mmHg) 18 14–23 21 17–26 0.40
PAOP(mmHg) 10 8–12 12 9–14 0.23
CI (l/minute/m2) 3.57 3.08–4.39 3.61 3.05–3.90 0.90
SVR (dyn/s/cm-5) 683 536–876 578 503–868 0.75
PVR (dyn/s/cm-5) 95 58–126 91 74–120 0.38
EVLWI (ml/kg/m2) 7.0 6.0–9.0 7.0 7.0–8.0 0.71
ITBVI (ml/kg/m2) 844 797–1,093 788 728–948 0.12
After admission to ICU
MAP (mmHg) 85 75–92 85 73–90 0.49
CVP (mmHg) 10 8–13 12 8–13 0.82
MPAP (mmHg) 21 18–25 22 15–24 0.59
PAOP (mmHg) 12 10–16 11 9–13 0.21
CI (l/minute/m2) 3.00 2.70–3.37 3.19 2.84–3.69 0.25
SVR (dyn/s/cm-5) 952 797–1,163 814 744–981 0.10
PVR (dyn/s/cm-5) 105 74–149 106 84–130 0.76
EVLWI (ml/kg/m2) 6.1 5.0–8.0 6.4 5.8–7.2 0.71
ITBVI (ml/kg/m2) 916 826–1,091 900 820–1,137 0.95
6 hours after admission to ICU
MAP (mmHg) 80 75–86 73 68–82 0.07
CVP (mmHg) 10 7–13 11 8–12 0.95
MPAP (mmHg) 19 16–22 19 16–21 0.71
PAOP (mmHg) 12 10–14 11 9–15 0.74
CI (l/minute/m2) 2,9 2,4–3,3 3,0 2,6–3,4 0.68
SVR (dyn/s/cm-5) 878 719–1,213 875 612–974 0.51Critical Care    Vol 10 No 2    von Heymann et al.
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Moreover, an Hct as low as 20% during normothermic CPB
was not associated with a higher incidence of acute renal fail-
ure (2/54 (3.7%) patients, 1 patient in each group), which con-
firms previous results [27]. It has to be assumed that oxygen
delivery to the kidneys was maintained since postoperative
creatinine levels, urine volumes and usage of loop diuretics
(data not shown) were not significantly different between
groups. This may suggest that an Hct of 20% during CPB may
preserve renal function in patients without preoperative renal
impairment. These results are in contrast to recent studies
[28,29] reporting an association between low Hct during CPB
and acute renal failure, although these studies were not able
to show a cause-effect relationship for low Hct and acute renal
failure.
The median stay in the ICU in our patients was 22 hours in the
25% Hct group versus 23 hours in the 20% Hct group (p =
0.24) and confirms previous results from elective CABG sur-
gery [30]. The combined endpoint of postoperative organ fail-
ure (neurological, cardiac, respiratory and renal) was not
significantly different between groups and may have contrib-
uted to this outcome. This may indicate that an Hct of 20%
during normothermic CPB in a group of low-risk CABG
patients does not necessarily impair clinical outcome.
Study limitations
Our study does have some limitations. First, the sample size of
this pilot study was generally not large enough to detect the
differences observed with sufficient power. Therefore, our
results may serve as a database for larger studies investigating
the effect of hemodilution during CPB. A power calculation for
the outcome 'ICU stay' with the given sample sizes would cor-
respond to a power of not mor e  t h a n  2 0 %  f o r  ' I C U  s t a y '
whereas for 'oxygen delivery (DO2)' would result in a sufficient
power of more than 80%. A sufficiently powered clinical trial
investigating 'mortality' as a clinical endpoint would require a
far larger number of patients to detect a clinically relevant dif-
ference between the groups.
Second, patients studied were low risk patients. This pre-
cludes that our results can be generalized to cardiac patients
with certain comorbidities in whom an individual risk-benefit
analysis prior to transfusion is required. A univariate analysis of
all risk factors that may have influenced the length of ICU stay
was performed but did not find the lowest Hct during CPB to
be predictive for ICU stay. Therefore, and due to the limited
sample size, a multivariate analysis was not considered appro-
priate. Third, there were only two women in our study popula-
tion, which does not reflect the gender distribution of CABG
patients. In particular, women with a lower body weight are at
risk of being exposed to a low Hct and allogeneic blood prod-
ucts during CPB. Therefore, our results need to be confirmed
in a larger study including a sufficient number of women.
Fourth, five times as many patients in the 20% Hct group were
transfused after surgery. This was not statistically significant (p
= 0.1) but may have become so in a larger study. Transfusions
in the postoperative period may have non-beneficial effects on
safety and outcome in cardiac surgery [3,4] and need to be as
closely controlled as possible during CPB. Using a more
restrictive transfusion threshold as suggested by Paone and
colleagues [31], who transfused cardiac surgical patients in
the ICU at an Hct of less than 20% without observing any
adverse effects on outcome. This may have prevented some
patients from being transfused in our study.
PVR (dyn/s/cm-5) 110 78–143 88 79–118 0.18
EVLWI (ml/kg/m2) 6.1 5.4–7.0 6.6 5.2–7.2 0.49
ITBVI (ml/kg/m2) 971 863–1,034 883 795–1,088 0.61
Before discharge from ICU
MAP (mmHg) 81 73–90 83 69–89 0.49
CVP (mmHg) 9 6–13 9 6–11 0.76
MPAP (mmHg) 17 14–19 19 16–23 0.06
PAOP (mmHg) 12 9–14 13 10–16 0.32
CI (l/minute/m2) 3.33 2.84–3.88 2.95 2.64–3.47 0.31
SVR (dyn/s/cm-5) 848 694–1,053 756 629–963 0.63
PVR (dyn/s/cm-5) 51 34–88 82 43–118 0.18
EVLWI (ml/kg/m2) 5.9 5.3–7.7 6.0 5.4–6.8 0.94
ITBVI (ml/kg/m2) 994 857–1,159 958 833–1,132 0.92
CI, cardiac index; CPB, cardiopulmonary bypass; CVP, central venous pressure; EVLWI, extravascular lung water index; ICU, intensive care unit; 
IQR, interquartile range; ITBVI, intrathoracic blood volume index; MAP, mean arterial pressure; MPAP, mean pulmonary artery pressure; PAOP, 
pulmonary artery occlusion pressure; SVR, systemic vascular resistance; PVR, pulmonary vascular resistance.
Table 4 (Continued)
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Conclusion
Our results from a small and low risk group of CABG patients
suggest that hemodilution to an Hct of 20% during normoth-
ermic CPB did not induce a 'critical' imbalance between oxy-
gen delivery and consumption that would have resulted in a
worse clinical outcome. Although these results require confir-
mation by larger studies, patients without severe comorbidities
who are at a high risk of receiving allogeneic blood products
may safely tolerate an Hct of 20% during normothermic CPB.
If further investigations determine an Hct of 20% during nor-
mothermic CPB to be safe, a reduction in exposure to alloge-
neic blood products seems to be possible.
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